NCT00219817: Safety and Efficacy of RC-1291 HCl in Patients With Cancer Related Anorexia…

Summary

Anorexia and weight loss are devastating complications in late-stage cancer patients and is strongly associated with mortality in these patients. Activation of Ghrelin receptors have been demonstrated to stimulate appetite. RC-1291 HCl, by virtue of its ghrelin like activity and Growth Hormone releasing effects may have a dual role in the reversal of cancer induced anorexia and weight loss. This study will test the safety and efficacy of RC-1291 in the treatment of cancer patients with anorexia and weight loss.

Timeline

Start: 2005-06
Primary completion: 2006-10
Completion: 2006-10

Outcome

Met primary endpoint

paper difference 2.09 kg [0.94-3.25]; p=0.0006 PMID 25524795 ↗

Publications

Garcia JM, Boccia RV, Graham CD, Yan Y, Duus EM, Allen S, Friend J. Anamorelin for patients with cancer cachexia: an integrated analysis of two phase 2, randomised, placebo-controlled, double-blind trials. Lancet Oncol. 2015 Jan;16(1):108-16. doi: 10.1016/S1470-2045(14)71154-4. Epub 2014 Dec 16.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Anamorelin	Small molecule	50 mg	Oral

Indications

No indication recorded.